$CHRS
Coherus BioSciences Inc

2021 Q4 Form 10-Q Financial Statement

#000155837021015033 Filed on November 08, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q3
Revenue $73.37M $82.50M $113.6M
YoY Change -33.54% -27.34% 1.67%
Cost Of Revenue $12.10M $21.28M $9.000M
YoY Change 3.45% 136.44% 40.63%
Gross Profit $61.27M $61.22M $104.6M
YoY Change -37.93% -41.44% -0.65%
Gross Profit Margin 83.5% 74.21% 92.07%
Selling, General & Admin $50.05M $39.93M $31.98M
YoY Change 32.76% 24.83% 0.49%
% of Gross Profit 81.69% 65.21% 30.59%
Research & Development $50.76M $54.09M $38.85M
YoY Change 13.82% 39.21% 80.13%
% of Gross Profit 82.85% 88.34% 37.16%
Depreciation & Amortization $836.0K $892.0K $600.0K
YoY Change -7.11% 48.67% -25.0%
% of Gross Profit 1.36% 1.46% 0.57%
Operating Expenses $100.8M $94.01M $79.84M
YoY Change 22.5% 17.76% 33.41%
Operating Profit -$39.55M -$32.79M $33.72M
YoY Change -341.14% -197.24% -34.96%
Interest Expense -$5.793M $5.771M $5.656M
YoY Change 1.63% 2.03% 26.56%
% of Operating Profit 16.78%
Other Income/Expense, Net -$385.0K $30.00K $56.00K
YoY Change -46.43% -89.19%
Pretax Income -$45.73M -$38.53M $28.12M
YoY Change -523.38% -237.03% -41.29%
Income Tax $0.00 $0.00 $200.0K
% Of Pretax Income 0.71%
Net Earnings -$45.73M -$38.53M $27.93M
YoY Change -571.39% -237.93% -40.62%
Net Earnings / Revenue -62.32% -46.7% 24.6%
Basic Earnings Per Share -$0.49 $0.39
Diluted Earnings Per Share -$595.0K -$0.49 $0.33
COMMON SHARES
Basic Shares Outstanding 76.79M 79.01M 71.65M
Diluted Shares Outstanding 79.01M 87.47M

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $417.2M $468.7M $503.4M
YoY Change -22.91% -6.89% 195.25%
Cash & Equivalents $417.2M $360.5M $292.5M
Short-Term Investments $0.00 $108.2M $211.0M
Other Short-Term Assets $24.46M $30.40M $27.50M
YoY Change -2.14% 10.56% 219.77%
Inventory $37.64M $37.58M $35.25M
Prepaid Expenses
Receivables $123.0M $136.3M $160.7M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $602.3M $673.0M $726.9M
YoY Change -21.52% -7.41% 163.02%
LONG-TERM ASSETS
Property, Plant & Equipment $7.813M $8.505M $21.10M
YoY Change -22.7% -59.69% 260.25%
Goodwill $943.0K $943.0K $943.0K
YoY Change 0.0% 0.0% 0.0%
Intangibles $2.620M $2.620M $2.620M
YoY Change 0.0% 0.0% 0.0%
Long-Term Investments
YoY Change
Other Assets $10.03M $10.26M $976.0K
YoY Change -20.07% 951.43% 89.88%
Total Long-Term Assets $77.01M $68.69M $76.81M
YoY Change 3.83% -10.58% 50.59%
TOTAL ASSETS
Total Short-Term Assets $602.3M $673.0M $726.9M
Total Long-Term Assets $77.01M $68.69M $76.81M
Total Assets $679.3M $741.7M $803.7M
YoY Change -19.29% -7.71% 145.5%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $16.16M $45.71M $11.99M
YoY Change 6.3% 281.21% -12.54%
Accrued Expenses $48.13M $45.83M $23.45M
YoY Change 80.39% 95.45% 42.32%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $741.0K $125.3M $500.0K
YoY Change 23.5% 24955.6%
Total Short-Term Liabilities $165.3M $320.3M $133.4M
YoY Change 13.51% 140.08% 61.34%
LONG-TERM LIABILITIES
Long-Term Debt $408.8M $281.9M $404.0M
YoY Change 0.96% -30.22% 127.22%
Other Long-Term Liabilities $750.0K $750.0K $705.0K
YoY Change -28.64% 6.38%
Total Long-Term Liabilities $750.0K $750.0K $705.0K
YoY Change -28.64% 6.38%
TOTAL LIABILITIES
Total Short-Term Liabilities $165.3M $320.3M $133.4M
Total Long-Term Liabilities $750.0K $750.0K $705.0K
Total Liabilities $581.6M $611.0M $548.0M
YoY Change 3.73% 11.49% 101.95%
SHAREHOLDERS EQUITY
Retained Earnings -$1.050B -$1.004B -$772.5M
YoY Change 37.64% 29.99%
Common Stock $7.000K $7.000K $1.028B
YoY Change 0.0% -100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $97.73M $130.8M $255.7M
YoY Change
Total Liabilities & Shareholders Equity $679.3M $741.7M $803.7M
YoY Change -19.29% -7.71% 145.49%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q3
OPERATING ACTIVITIES
Net Income -$45.73M -$38.53M $27.93M
YoY Change -571.39% -237.93% -40.62%
Depreciation, Depletion And Amortization $836.0K $892.0K $600.0K
YoY Change -7.11% 48.67% -25.0%
Cash From Operating Activities -$52.32M $13.71M $47.30M
YoY Change -258.07% -71.01% -13.84%
INVESTING ACTIVITIES
Capital Expenditures -$468.0K -$261.0K -$2.100M
YoY Change -48.0% -87.57% 133.33%
Acquisitions
YoY Change
Other Investing Activities $108.0M $16.25M $18.50M
YoY Change -48.84% -12.16% 2542.86%
Cash From Investing Activities $107.5M $15.99M $16.40M
YoY Change -48.84% -2.5% -5566.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.487M 1.101M 4.100M
YoY Change -72.96% -73.15% 10.81%
NET CHANGE
Cash From Operating Activities -52.32M 13.71M 47.30M
Cash From Investing Activities 107.5M 15.99M 16.40M
Cash From Financing Activities 1.487M 1.101M 4.100M
Net Change In Cash 56.65M 30.80M 67.80M
YoY Change -77.22% -54.57% 16.3%
FREE CASH FLOW
Cash From Operating Activities -$52.32M $13.71M $47.30M
Capital Expenditures -$468.0K -$261.0K -$2.100M
Free Cash Flow -$51.85M $13.97M $49.40M
YoY Change -252.51% -71.72% -11.47%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q3 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
usgaap:ProductMember
us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
usgaap:ProductMember
CY2021Q3 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
usgaap:ProductMember
dei Entity Central Index Key
EntityCentralIndexKey
0001512762
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2021Q3 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2020Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2021Q3 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2020Q4 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2021Q3 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2020Q4 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
CY2020 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
CY2020 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
72513348
dei Document Type
DocumentType
10-Q
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
76583279
us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
usgaap:ProductMember
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36721
dei Entity Registrant Name
EntityRegistrantName
Coherus BioSciences, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-3615821
dei Entity Address Address Line1
EntityAddressAddressLine1
333 Twin Dolphin Drive
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 600
dei Entity Address City Or Town
EntityAddressCityOrTown
Redwood City
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94065
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
649-3530
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
CHRS
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
76785431
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
360540000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
541158000
CY2021Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
108167000
CY2021Q3 us-gaap Receivables Net Current
ReceivablesNetCurrent
136346000
CY2020Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
157046000
CY2021Q3 us-gaap Inventory Net
InventoryNet
37583000
CY2020Q4 us-gaap Inventory Net
InventoryNet
44233000
CY2021Q3 chrs Prepaid Manufacturing Expense Current
PrepaidManufacturingExpenseCurrent
20378000
CY2020Q4 chrs Prepaid Manufacturing Expense Current
PrepaidManufacturingExpenseCurrent
19429000
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10025000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5613000
CY2021Q3 us-gaap Assets Current
AssetsCurrent
673039000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
767479000
CY2021Q3 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
8505000
CY2020Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
10108000
CY2021Q3 us-gaap Inventory Noncurrent
InventoryNoncurrent
46357000
CY2020Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
47956000
CY2021Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2620000
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2620000
CY2021Q3 us-gaap Goodwill
Goodwill
943000
CY2020Q4 us-gaap Goodwill
Goodwill
943000
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
10262000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
12543000
CY2021Q3 us-gaap Assets
Assets
741726000
CY2020Q4 us-gaap Assets
Assets
841649000
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
45707000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
15201000
CY2021Q3 chrs Accrued Rebates Fees And Reserve Current
AccruedRebatesFeesAndReserveCurrent
84744000
CY2020Q4 chrs Accrued Rebates Fees And Reserve Current
AccruedRebatesFeesAndReserveCurrent
81529000
CY2021Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
18793000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
22244000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
45826000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
26679000
CY2021Q3 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
80978000
CY2021Q3 chrs Convertible Notes Payable Current Related Party
ConvertibleNotesPayableCurrentRelatedParty
26992000
CY2021Q3 us-gaap Loans Payable Current
LoansPayableCurrent
17308000
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
320348000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
145653000
CY2020Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
79885000
CY2021Q3 us-gaap Convertible Subordinated Debt Noncurrent
ConvertibleSubordinatedDebtNoncurrent
223971000
CY2020Q4 us-gaap Convertible Subordinated Debt Noncurrent
ConvertibleSubordinatedDebtNoncurrent
223029000
CY2021Q3 us-gaap Long Term Loans Payable
LongTermLoansPayable
57924000
CY2020Q4 us-gaap Long Term Loans Payable
LongTermLoansPayable
74481000
CY2021Q3 chrs Operating And Finance Lease Liability Noncurrent
OperatingAndFinanceLeaseLiabilityNoncurrent
7973000
CY2020Q4 chrs Operating And Finance Lease Liability Noncurrent
OperatingAndFinanceLeaseLiabilityNoncurrent
9948000
CY2021Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
750000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1051000
CY2021Q3 us-gaap Liabilities
Liabilities
610966000
CY2020Q4 us-gaap Liabilities
Liabilities
560675000
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
76583279
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
72513348
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
7000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
7000
CY2021Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1135155000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1043991000
CY2021Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-273000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-270000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1004129000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-762754000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
130760000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
280974000
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
741726000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
841649000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
124947000
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
183000
CY2021Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
82503000
CY2020Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
113551000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
253180000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
365405000
CY2021Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
21280000
CY2020Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
9000000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
45487000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
25994000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
54085000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
38851000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
312343000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
98131000
CY2021Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
39925000
CY2020Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
31984000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
119661000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
101386000
CY2021Q3 us-gaap Costs And Expenses
CostsAndExpenses
115290000
CY2020Q3 us-gaap Costs And Expenses
CostsAndExpenses
79835000
us-gaap Costs And Expenses
CostsAndExpenses
477491000
us-gaap Costs And Expenses
CostsAndExpenses
225511000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-32787000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
33716000
us-gaap Operating Income Loss
OperatingIncomeLoss
-224311000
us-gaap Operating Income Loss
OperatingIncomeLoss
139894000
CY2021Q3 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
637000
CY2020Q3 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
625000
us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
1902000
us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
1867000
CY2021Q3 us-gaap Interest Expense
InterestExpense
5771000
CY2020Q3 us-gaap Interest Expense
InterestExpense
5656000
us-gaap Interest Expense
InterestExpense
17166000
us-gaap Interest Expense
InterestExpense
15495000
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
30000
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
56000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
102000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
548000
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-38528000
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
28116000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-241375000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2411000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-38528000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
27933000
us-gaap Net Income Loss
NetIncomeLoss
-241375000
us-gaap Net Income Loss
NetIncomeLoss
122536000
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.49
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.39
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.22
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.72
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.49
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.33
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.22
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.52
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
79013240
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
71649350
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
74984811
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
71138973
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
79013240
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
87470337
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
74984811
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
82043469
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-38528000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
27933000
us-gaap Net Income Loss
NetIncomeLoss
-241375000
us-gaap Net Income Loss
NetIncomeLoss
122536000
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-6000
CY2020Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
6000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-3000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
18000
CY2020Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-4000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
0
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
285000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-38534000
CY2020Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
27935000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-241378000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
122839000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
280974000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4429000
CY2021Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
1730000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
16982000
CY2021Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-37000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-172947000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
127671000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4009000
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
40903000
CY2021Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1985000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11512000
CY2021Q2 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
40000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-29900000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
156220000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1288000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11786000
CY2021Q3 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-6000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-38528000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
130760000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
105214000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4438000
CY2020Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2378000
CY2020Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
880000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9945000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
35572000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
157275000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3305000
CY2020Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2557000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9686000
CY2020Q2 chrs Purchase Of Capped Call Options Relates To Convertible Notes Value
PurchaseOfCappedCallOptionsRelatesToConvertibleNotesValue
-18170000
CY2020Q2 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
12000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
59031000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
213377000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4962000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9457000
CY2020Q3 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
6000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
27933000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
255731000
us-gaap Profit Loss
ProfitLoss
-241375000
us-gaap Profit Loss
ProfitLoss
122536000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2618000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2048000
us-gaap Share Based Compensation
ShareBasedCompensation
40418000
us-gaap Share Based Compensation
ShareBasedCompensation
28287000
us-gaap Gain Loss On Contract Termination
GainLossOnContractTermination
-3210000
us-gaap Inventory Write Down
InventoryWriteDown
5192000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-909000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
103000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
3150000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
2492000
chrs Non Cash Operating Lease Expense
NonCashOperatingLeaseExpense
1618000
chrs Non Cash Operating Lease Expense
NonCashOperatingLeaseExpense
1567000
chrs Upfront License Fee Payments Related To License And Collaboration Arrangements
UpfrontLicenseFeePaymentsRelatedToLicenseAndCollaborationArrangements
136000000
chrs Upfront And Milestone Based License Fee Payments
UpfrontAndMilestoneBasedLicenseFeePayments
7500000
chrs Other Noncash Adjustments
OtherNoncashAdjustments
181000
chrs Other Noncash Adjustments
OtherNoncashAdjustments
422000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-20722000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
18885000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-2936000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
30053000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
2884000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
13350000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4590000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
785000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
30495000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-13108000
chrs Increase Decrease In Accrued Rebates Fees And Reserve
IncreaseDecreaseInAccruedRebatesFeesAndReserve
3215000
chrs Increase Decrease In Accrued Rebates Fees And Reserve
IncreaseDecreaseInAccruedRebatesFeesAndReserve
24841000
chrs Increase Decrease In Accrued Compensation
IncreaseDecreaseInAccruedCompensation
-3451000
chrs Increase Decrease In Accrued Compensation
IncreaseDecreaseInAccruedCompensation
1380000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
16526000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
6232000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
14890000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
121021000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
821000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6279000
us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
167000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
171779000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
63000000
chrs Upfront And Milestone Payments Related To License And Collaboration Arrangements
UpfrontAndMilestonePaymentsRelatedToLicenseAndCollaborationArrangements
136000000
chrs Upfront And Milestone Based License Fee Payments Investing Activities
UpfrontAndMilestoneBasedLicenseFeePaymentsInvestingActivities
7500000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
273845000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
62700000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-245900000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-224457000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
222156000
chrs Payments To Acquire Capped Call Options Related To Convertible Debt
PaymentsToAcquireCappedCallOptionsRelatedToConvertibleDebt
18170000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
40903000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
9726000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
13014000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
1985000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
2557000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1730000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
880000
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-492000
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-244000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
50392000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
218433000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-180618000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
114997000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
541598000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
177908000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
360980000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
292905000
chrs Non Cash Bonus Payment Settled In Common Stock
NonCashBonusPaymentSettledInCommonStock
1498000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
434000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1388000
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
477000
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
1771000
chrs Number Of Products
NumberOfProducts
4
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make judgements, estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. These estimates form the basis for making judgments about the carrying values of assets and liabilities when these values are not readily apparent from other sources. Accounting estimates and judgements are inherently uncertain and the actual results could differ from these estimates.</p>
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
541158000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
177668000
CY2020Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
440000
CY2019Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
240000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
541598000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
177908000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
360540000
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
292465000
CY2021Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
440000
CY2020Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
440000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
360980000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
292905000
CY2021Q3 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2020Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
chrs Available For Sale Marketable Securities Average Maturity Term
AvailableForSaleMarketableSecuritiesAverageMaturityTerm
P11M
CY2021Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
0
us-gaap Provision For Loan Losses Expensed
ProvisionForLoanLossesExpensed
0
CY2020Q3 us-gaap Provision For Loan Losses Expensed
ProvisionForLoanLossesExpensed
0
us-gaap Provision For Loan Losses Expensed
ProvisionForLoanLossesExpensed
0
CY2021Q3 us-gaap Provision For Loan Losses Expensed
ProvisionForLoanLossesExpensed
0
CY2021Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
5617000
CY2020Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
5205000
CY2021Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
46625000
CY2020Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
43952000
CY2021Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
31698000
CY2020Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
43032000
CY2021Q3 us-gaap Inventory Gross
InventoryGross
83940000
CY2020Q4 us-gaap Inventory Gross
InventoryGross
92189000
CY2021Q3 us-gaap Inventory Net
InventoryNet
37583000
CY2020Q4 us-gaap Inventory Net
InventoryNet
44233000
CY2021Q3 us-gaap Inventory Noncurrent
InventoryNoncurrent
46357000
CY2020Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
47956000
CY2021Q3 chrs Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
83940000
CY2020Q4 chrs Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
92189000
CY2021Q3 chrs Inventory Write Off
InventoryWriteOff
5200000
CY2021Q3 chrs Prepaid Manufacturing Expense Current
PrepaidManufacturingExpenseCurrent
20400000
CY2020Q4 chrs Prepaid Manufacturing Expense Current
PrepaidManufacturingExpenseCurrent
19400000
CY2021Q1 us-gaap Gain Loss On Contract Termination
GainLossOnContractTermination
-3200000
CY2021Q1 chrs Cancellation Of Open Purchase Orders With Various Vendors
CancellationOfOpenPurchaseOrdersWithVariousVendors
8300000
CY2021Q2 chrs Cancellation Of Open Purchase Orders With Various Vendors
CancellationOfOpenPurchaseOrdersWithVariousVendors
0
CY2021Q3 chrs Cancellation Of Open Purchase Orders With Various Vendors
CancellationOfOpenPurchaseOrdersWithVariousVendors
0
chrs Reserve For Sales Discounts And Allowances Constitute Variable Consideration
ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration
520917000
chrs Provision Related To Sales Made In Prior Period
ProvisionRelatedToSalesMadeInPriorPeriod
-8715000
chrs Payments And Customer Credits Issued From Reserve For Discounts And Allowances Constitute Variable Consideration
PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration
516557000
CY2021Q3 chrs Reserve For Discounts And Allowances Constitute Variable Consideration
ReserveForDiscountsAndAllowancesConstituteVariableConsideration
119043000
CY2020Q4 chrs Reserve For Discounts And Allowances Constitute Variable Consideration
ReserveForDiscountsAndAllowancesConstituteVariableConsideration
123398000
CY2019Q4 chrs Reserve For Discounts And Allowances Constitute Variable Consideration
ReserveForDiscountsAndAllowancesConstituteVariableConsideration
87147000
chrs Reserve For Sales Discounts And Allowances Constitute Variable Consideration
ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration
488998000
chrs Provision Related To Sales Made In Prior Period
ProvisionRelatedToSalesMadeInPriorPeriod
-9763000
chrs Payments And Customer Credits Issued From Reserve For Discounts And Allowances Constitute Variable Consideration
PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration
464953000
CY2020Q3 chrs Reserve For Discounts And Allowances Constitute Variable Consideration
ReserveForDiscountsAndAllowancesConstituteVariableConsideration
101429000
CY2021Q3 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
27547000
CY2020Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
26158000
CY2021Q3 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
19042000
CY2020Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
16050000
CY2021Q3 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
8505000
CY2020Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
10108000
CY2021Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
900000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2600000
CY2020Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
700000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2000000.0
CY2021Q3 chrs Accrued Clinical And Manufacturing Liabilities Current
AccruedClinicalAndManufacturingLiabilitiesCurrent
21093000
CY2020Q4 chrs Accrued Clinical And Manufacturing Liabilities Current
AccruedClinicalAndManufacturingLiabilitiesCurrent
11365000
CY2021Q3 chrs Accrued Co Development Costs For Toripalimab Current
AccruedCoDevelopmentCostsForToripalimabCurrent
11239000
CY2021Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
9870000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
12182000
CY2021Q3 chrs Lease Liabilities Operating And Financing
LeaseLiabilitiesOperatingAndFinancing
3624000
CY2020Q4 chrs Lease Liabilities Operating And Financing
LeaseLiabilitiesOperatingAndFinancing
3132000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
45826000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
26679000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
74984811
CY2020Q2 chrs Equivalent To Conversion Price Per Common Share
EquivalentToConversionPricePerCommonShare
14.815
CY2021Q3 us-gaap Loans Payable Current
LoansPayableCurrent
17300000
CY2021Q3 us-gaap Purchase Obligation Future Minimum Payments Remainder Of Fiscal Year
PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear
16760000
CY2021Q3 us-gaap Purchase Obligation Due In Next Twelve Months
PurchaseObligationDueInNextTwelveMonths
34606000
CY2021Q3 us-gaap Purchase Obligation Due In Second Year
PurchaseObligationDueInSecondYear
9753000
CY2021Q3 us-gaap Purchase Obligation Due In Third Year
PurchaseObligationDueInThirdYear
3441000
CY2021Q3 us-gaap Purchase Obligation
PurchaseObligation
64560000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-38528000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
27933000
us-gaap Net Income Loss
NetIncomeLoss
-241375000
us-gaap Net Income Loss
NetIncomeLoss
122536000
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
79013240
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
71649350
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
74984811
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
71138973
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.49
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.39
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.22
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.72
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-38528000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
27933000
us-gaap Net Income Loss
NetIncomeLoss
-241375000
us-gaap Net Income Loss
NetIncomeLoss
122536000
CY2020Q3 us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
1172000
us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
2134000
CY2021Q3 us-gaap Net Income Loss Attributable To Parent Diluted
NetIncomeLossAttributableToParentDiluted
-38528000
CY2020Q3 us-gaap Net Income Loss Attributable To Parent Diluted
NetIncomeLossAttributableToParentDiluted
29105000
us-gaap Net Income Loss Attributable To Parent Diluted
NetIncomeLossAttributableToParentDiluted
-241375000
us-gaap Net Income Loss Attributable To Parent Diluted
NetIncomeLossAttributableToParentDiluted
124670000
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
79013240
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
71649350
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
71138973
CY2020Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
3641721
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
3505479
CY2020Q3 us-gaap Incremental Common Shares Attributable To Contingently Issuable Shares
IncrementalCommonSharesAttributableToContingentlyIssuableShares
237114
us-gaap Incremental Common Shares Attributable To Contingently Issuable Shares
IncrementalCommonSharesAttributableToContingentlyIssuableShares
143146
CY2020Q3 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
11942152
us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
7255871
CY2021Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
79013240
CY2020Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
87470337
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
74984811
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
82043469
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.49
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.33
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.22
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.52
CY2021Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
37875696
CY2020Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13871584
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
38076739
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13750170
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
200000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2400000

Files In Submission

Name View Source Status
0001558370-21-015033-index-headers.html Edgar Link pending
0001558370-21-015033-index.html Edgar Link pending
0001558370-21-015033.txt Edgar Link pending
0001558370-21-015033-xbrl.zip Edgar Link pending
chrs-20210930.xsd Edgar Link pending
chrs-20210930x10q.htm Edgar Link pending
chrs-20210930x10q_htm.xml Edgar Link completed
chrs-20210930xex31d1.htm Edgar Link pending
chrs-20210930xex31d2.htm Edgar Link pending
chrs-20210930xex32d1.htm Edgar Link pending
chrs-20210930_cal.xml Edgar Link unprocessable
chrs-20210930_def.xml Edgar Link unprocessable
chrs-20210930_lab.xml Edgar Link unprocessable
chrs-20210930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending